• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urologia internationalis >Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy
【24h】

Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy

机译：雄激素剥夺疗法和救赎放疗与抢救放疗的组合单独用于自由基前列腺癌中的复发放射治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: To assess the value of androgen deprivation therapy (ADT) on salvage radiotherapy (RT) in post-prostatectomy recurrent prostate cancer patients, we compared the oncologic outcomes between patients receiving RT + ADT and those receiving RT alone. Materials and Methods: We reviewed the records of patients diagnosed with prostate cancer between 1995 and 2011, including 93 patients who underwent salvage RT and 69 patients who underwent salvage RT + ADT. The ADT-free duration after withdrawal was calculated to verify testosterone recovery. Results: Presalvage prostate serum antigen (PSA) was the only significantly different characteristic between the 2 groups (p 80% of patients. Presalvage PSA = 0.6 ng/mL, pathologic stage = T3b, and RT + ADT were significantly associated with biochemical progression after salvage treatment. RT + ADT reduced biochemical progression in patients with seminal vesicle invasion or presalvage PSA = 0.6 ng/mL (p = 0.001) compared to RT alone; biochemical progression-free probability was unchanged in seminal vesicle noninvasive prostate cancer patients with presalvage PSA < 0.6 ng/mL (p = 0.541). Conclusions: RT + ADT reduced the risk of biochemical progression after salvage treatment in patients with seminal vesicle invasion or presalvage PSA = 0.6 ng/mL, but had no effect in patients with seminal vesicle noninvasive disease and presalvage PSA < 0.6 ng/mL. (C) 2017 S. Karger AG, Basel
机译：简介：为了评估前列腺切除术复发前列腺癌症患者的雄激素剥夺治疗（ADT）对挽救症放疗（RT）的价值，我们比较了接受RT + ADT的患者与接受RT的患者之间的肿瘤结果。材料和方法：我们审查了1995年至2011年期间患有前列腺癌的患者的记录，其中93名患者接受了拯救了59名患者的拯救了RT + ADT。试论退出后的无ADT的持续时间以验证睾丸激素恢复。结果：预售前列腺血清抗原（PSA）是2组（P 80％的患者的唯一明显不同的特征）。预先衰老PSA = 0.6ng / ml，病理阶段= T3b和RT + ADT与生化进展显着相关挽救治疗。RT + ADT与单独的单独进行结晶囊泡侵袭或预售PSA = 0.6ng / ml（p = 0.001）减少生化进展;在全面的囊泡无泡前列腺癌患者中，生化进展的概率不变，预售PSA患者不变<0.6ng / ml（p = 0.541）。结论：RT + ADT降低了抗精囊侵袭或预售PSA患者的持续损失后生化进展的风险= 0.6ng / ml，但患有精囊非侵入性的患者没有任何影响疾病和预售PSA <0.6 ng / ml。（c）2017年karger AG，巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号